Alternatively, if the dosing conditions of oral semaglutide are not suitable, whether it be due to a patient preference to avoid the fasting period or patients receiving other medications with potentially conflicting dosing conditions, then the once-weekly s.c
Doses of semaglutide ranging from 0.1-1.6 mg resulted in a 2.1%, 7.0%, 13.0%, 37.5%, 51.2%, and 63.6% respective dose-dependent increases in the proportion of patients that achieved a 5%, or greater, reduction in weight loss
While there is no definitive evidence that tirzepatide causes MTC in humans, the FDA requires a boxed warning, and the medication should not be used in patients with these risk factors
Achieving optimal blood sugar control typically takes several weeks, as we work together to find the best dosage for you